[1] CAVAZZONI E,BUGIANTELLA W,GRAZIOSI L,et al.Malignant ascites:pathophysiology and treatment[J].Int J Clin Oncol,2013,18(1):1-9.
[2] SUNG H,FERLAY J,SIEGEL R L,et al.Global Cancer Statistics 2020:GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA Cancer J Clin,2021,71(3):209-249.
[3] LISIO M A,FU L,GOYENECHE A,et al.High-grade serous ovarian cancer:basic sciences, clinical and therapeutic standpoints[J].Int J Mol Sci,2019,20(4):952.
[4] KRUGMANN J,SCHWARZ C L,MELCHER B,et al.Malignant ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis:a retrospective analysis of 191 women treated at Bayreuth Hospital,2006-2015[J].Arch Gynecol Obstet,2019,299(2):515-523.
[5] IZAR B,TIROSH I,STOVER E H,et al.A single-cell landscape of high-grade serous ovarian cancer[J].Nat Med,2020,26(8):1271-1279.
[6] URUSKI P,MIKUłA-PIETRASIK J,PAKUłA M,et al.Malignant ascites promote adhesion of ovarian cancer cells to peritoneal mesothelium and fibroblasts[J].Int J Mol Sci,2021,22(8):4222.
[7] BROWNING L,PATEL M R,HORVATH E B,et al.IL-6 and ovarian cancer:inflammatory cytokines in promotion of metastasis[J].Cancer Manag Res,2018,10:6685-6693.
[8] SZULC-KIELBIK I,KIELBIK M,NOWAK M,et al.The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells.Systematic review of its potential role as a biomarker in ovarian cancer patients[J].Biochim Biophys Acta Rev Cancer,2021,1876(2):188639.
[9] FAHMI M N,PRADJATMO H,ASTUTI I,et al.Cytokines as prognostic biomarkers of epithelial ovarian cancer(EOC):a systematic review and meta-analysis[J].Asian Pac J Cancer Prev,2021,22(2):315-323.
[10] AMER H,KARTIKASARI A E R,PLEBANSKI M.Elevated interleukin-6 levels in the circulation and peritoneal fluid of patients with ovarian cancer as a potential diagnostic biomarker:a systematic review and meta-analysis[J].J Pers Med,2021,11(12):1335.
[11] BRAICU E I,KRAUSE C L,TORSTEN U,et al.HE4 as a serum biomarker for the diagnosis of pelvic masses:a prospective,multicenter study in 965 patients[J].BMC Cancer,2022,22(1):831.
[12] KAMPAN N C,MADONDO M T,REYNOLDS J,et al.Pre-operative sera interleukin-6 in the diagnosis of high-grade serous ovarian cancer[J].Sci Rep,2020,10(1):2213.
[13] ITO T,HANAFUSA N,IWASE S,et al.Ascitic IL-10 concentration predicts prognosis of patients undergoing cell-free and concentrated ascites reinfusion therapy[J].Ther Apher Dial,2020,24(1):90-95.
[14] ZHAO Y,WANG H,HE C.Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation:from mechanism analysis to clinical strategy[J].J Cancer Res Clin Oncol,2021,147(12):3653-3664.
[15] ZHAN Z,WANG X,YU J,et al.Intraperitoneal infusion of recombinant human endostatin improves prognosis in gastric cancer ascites[J].Future Oncol,2022,18(10):1259-1271.
[16] TAO Y,TANG XT,LI X,et al.Comparison of neoadjuvant chemotherapy efficiency in advanced ovarian cancer patients treated with paclitaxel plus carboplatin and intraperitoneal bevacizumab vs. paclitaxel with carboplatin[J].Front Med(Lausanne),2022,9:807377.
[17] KUMARI A,SHONIBARE Z,MONAVARIAN M,et al.TGFβ signaling networks in ovarian cancer progression and plasticity[J].Clin Exp Metastasis,2021,38(2):139-161.
[18] SHONIBARE Z,MONAVARIAN M, O'CONNELL K,et al.Reciprocal SOX2 regulation by SMAD1-SMAD3 is critical for anoikis resistance and metastasis in cancer[J].Cell Rep,2022,40(4):111066.
[19] HAO Y,BAKER D,TEN DIJKE P.TGF-β-mediated epithelial-mesenchymal transition and cancer metastasis[J].Int J Mol Sci,2019,20(11):2767.
[20] BATLLE E,MASSAGUE J.Transforming growth factor-β signaling in immunity and cancer[J].Immunity,2019,50(4):924-940.
[21] BACI D,BOSI A,GALLAZZI M,et al.The ovarian cancer tumor immune microenvironment(TIME) as target for therapy:a focus on innate immunity cells as therapeutic effectors[J].Int J Mol Sci,2020,21(9):3125.
[22] RICKARD B P,CONRAD C,SORRIN A J,et al.Malignant ascites in ovarian cancer:cellular, acellular, and biophysical determinants of molecular characteristics and therapy response[J].Cancers(Basel),2021,13(17):4318.
[23] GONG Y,YANG J,WANG Y,et al.Metabolic factors contribute to T-cell inhibition in the ovarian cancer ascites[J].Int J Cancer,2020,147(7):1768-1777.
[24] CHEN R R,YUNG M M H,XUAN Y,et al.Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells[J].Commun Biol,2019,2:281.
[25] RADHAKRISHNAN R,HA J H,JAYARAMAN M,et al.Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts[J].Cancer Lett,2019,442:464-474.
[26] PENET M F,KRISHNAMACHARY B,WILDERS F B,et al. Ascites volumes and the ovarian cancer microenvironment[J].Front Oncol,2018,8:595.
[27] COMPTON S L E,GRIECO J P,GOLLAMUDI B,et al.Metabolic reprogramming of ovarian cancer spheroids during adhesion[J].Cancers(Basel),2022,14(6):1399.
[28] ZHANG Y,OUYANG D,CHEN Y H,et al.Peritoneal resident macrophages in tumor metastasis and immunotherapy[J].Front Cell Dev Biol,2022,10:948952.
[29] MIKUłA-PIETRASIK J,URUSKI P,SZUBERT S,et al.Malignant ascites determine the transmesothelial invasion of ovarian cancer cells[J].Int J Biochem Cell Biol,2017,92:6-13.
[30] XIE W,YU J,YIN Y,et al.OCT4 induces EMT and promotes ovarian cancer progression by regulating the PI3K/AKT/mTOR pathway[J].Front Oncol,2022,12:876257.
[31] ZHANG J,LI Y,LIU H,et al.Genome-wide CRISPR/Cas9 library screen identifies PCMT1 as a critical driver of ovarian cancer metastasis[J].J Exp Clin Cancer Res,2022,41(1):24.
[32] KLEINMANNS K,GULLAKSEN S E,BREDHOLT G,et al.Humanized ovarian cancer patient-derived xenografts for improved preclinical evaluation of immunotherapies[J].Cancers(Basel),2022,14(13):3092.
[33] READER J C,FAN C,ORY E C,et al.Microtentacle formation in ovarian carcinoma[J].Cancers(Basel),2022,14(3):800.
[34] LAI I.Correlation of differential ascites volume with primary cytoreductive surgery outcome,lymph node involvement,and disease recurrence in advanced ovarian cancer[J/OL].[2022-10-02].https://doi.org/10.1136/ijgc-2019-000310.
[35] PICHE A.Malignant peritoneal effusion acting as a tumor environment in ovarian cancer progression:impact and significance[J].World J Clin Oncol,2018,9(8):167-171.
[36] EMMINGS E,MULLANY S,CHANG Z,et al.Targeting mitochondria for treatment of chemoresistant ovarian cancer[J].Int J Mol Sci,2019,20(1):229.
[37] CAPELLERO S,ERRIQUEZ J,BATTISTINI C,et al.Ovarian cancer cells in ascites form aggregates that display a hybrid epithelial-mesenchymal phenotype and allows survival and proliferation of metastasizing cells[J].Int J Mol Sci,2022,23(2):833.
[38] PAULLIN T,POWELL C,MENZIE C,et al.Spheroid growth in ovarian cancer alters transcriptome responses for stress pathways and epigenetic responses[J].PLoS One,2017,12(8):e0182930.
[39] KIM S,LEE M,DHANASEKARAN D N,et al.Activation of LXRɑ/β by cholesterol in malignant ascites promotes chemoresistance in ovarian cancer[J].BMC Cancer,2018,18(1):1232.
[40] FARRELL R,LIAUW W S,MORRIS D L.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy(HIPEC) for ovarian cancer in an Australian institution:lessons from 20 years' experience[J].BMC Surg,2022,22(1):338.
[41] HOPPENOT C,ECKERT M A,TIENDA S M,et al.Who are the long-term survivors of high grade serous ovarian cancer?[J].Gynecol Oncol,2018,148(1):204-212.
[42] SZENDER I B,EMMONS T,BELLIOTTI S,et al.Impact of ascites volume on clinical outcomes in ovarian cancer:a cohort study[J].Gynecol Oncol,2017,146(3):491-497.
[43] LIEBER S,REINARTZ S,RAIFER H,et al.Prognosis of ovarian cancer is associated with effector memory CD8+ T cell accumulation in ascites,CXCL9 levels and activation-triggered signal transduction in T cells[J].Oncoimmunology,2018,7(5):e1424672. |
